Ketamine Injectable Product

DRUG4 trials

Sponsors

University of Pennsylvania, Hackensack Meridian Health, Melt Pharmaceuticals, Brian Anderson, MD

Conditions

Acute PainAnesthesia AwarenessDemoralizationGastrointestinal CancersHealthy VolunteersPain, AcutePancreatic Ductal Adenocarcinoma

Phase 1

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

CompletedNCT04485702

Melt PharmaceuticalsHealthy Volunteers

Start: 2020-07-20End: 2020-08-29Updated: 2021-02-23

Phase 2

A Study of Human Multi-Sensory Integration

SuspendedNCT03498391

University of PennsylvaniaAnesthesia Awareness

Start: 2018-07-30End: 2023-05-31Target: 40Updated: 2023-02-08

Phase 4

Ketamine for Pain in the Emergency Department

TerminatedNCT03896230

Hackensack Meridian HealthAcute Pain

Start: 2019-05-03End: 2019-12-20Updated: 2023-06-07

Ketamine-assisted Therapy for Advanced GI Cancer

TerminatedNCT06077487

Brian Anderson, MDDemoralization, Gastrointestinal Cancers, Pain, Acute +1

Start: 2024-05-17End: 2025-01-31Updated: 2025-05-21